Clinuvel Pharmaceuticals (CUV) H2 2024 earnings summary

Executive summary

• Achieved record financial results for FY2024, including the largest revenue and profit in company history, with an eighth consecutive annual profit and seventh consecutive annual dividend declared.

• Revenue growth was driven by increased demand for SCENESSE® in Europe and North America, supported by disciplined cost management and expansion in headcount and leadership.

• Strategic focus on reinvesting profits into R&D, pipeline development, and diversification into new jurisdictions and indications.

• Expansion strategy includes new product launches, adolescent use, and global prelaunch activities for photocosmetics.

• Maintained a differentiated model by leveraging four decades of melanocortin data and integrating pharma and photocosmetics.

Financial highlights

• Total revenues reached $95.3 million, up 15% year-over-year, with net profit after tax rising 16% to $35.6 million.

• Net profit before tax increased 11% to $50.7 million; EBIT margin was 53%, and net profit after tax margin was 37%.

• Cash reserves grew 17% to $183.9 million, and total assets increased 19% to $231 million.

• Basic EPS rose 15% to $0.72; net tangible assets per share increased 22% to $4.02.

• Fully franked dividend of $0.05 per share declared, with nearly $750,000 invested in share buybacks.

Outlook and guidance

• No formal guidance provided, but a new three-year expenses plan will be finalized in Q4 2024 and announced in H1 2025.

• Strong balance sheet and cash reserves enable pursuit of organic and inorganic growth, with continued disciplined capital deployment.

• Ongoing investment in R&D, new formulations, and in-house manufacturing integration.

• On track with 2024 objectives; new objectives to be presented at the AGM.